Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Exon-skipping advances for Duchenne muscular dystrophy
Lucía Echevarría, Philippine Aupy, Aurélie Goyenvalle
Human Molecular Genetics (2018) Vol. 27, Iss. R2, pp. R163-R172
Open Access | Times Cited: 103

Showing 1-25 of 103 citing articles:

CRISPR-Cas9 corrects Duchenne muscular dystrophy exon 44 deletion mutations in mice and human cells
Yi-Li Min, Hui Li, Cristina Rodríguez-Caycedo, et al.
Science Advances (2019) Vol. 5, Iss. 3
Open Access | Times Cited: 229
Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders
Marlen C. Lauffer, Willeke M. C. van Roon‐Mom, Annemieke Aartsma‐Rus
Communications Medicine (2024) Vol. 4, Iss. 1
Open Access | Times Cited: 82
Absorption, Distribution, Metabolism, and Excretion of US Food and Drug Administration–Approved Antisense Oligonucleotide Drugs
Julia M. Migliorati, Sunna Liu, Anna Liu, et al.
Drug Metabolism and Disposition (2022) Vol. 50, Iss. 6, pp. 888-897
Open Access | Times Cited: 74
Phase 1/2 trial of brogidirsen: Dual-targeting antisense oligonucleotides for exon 44 skipping in Duchenne muscular dystrophy
Hirofumi Komaki, Eri Takeshita, Katsuhiko Kunitake, et al.
Cell Reports Medicine (2025), pp. 101901-101901
Open Access | Times Cited: 2
Cardiac Pathophysiology and the Future of Cardiac Therapies in Duchenne Muscular Dystrophy
Tatyana A. Meyers, DeWayne Townsend
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 17, pp. 4098-4098
Open Access | Times Cited: 106
Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: Can we do better?
Stephanie Kourakis, Cara A. Timpani, Dean G. Campelj, et al.
Orphanet Journal of Rare Diseases (2021) Vol. 16, Iss. 1
Open Access | Times Cited: 70
Non-viral delivery of CRISPR–Cas9 complexes for targeted gene editing via a polymer delivery system
Jonathan O’Keeffe Ahern, Irene Lara‐Sáez, Dezhong Zhou, et al.
Gene Therapy (2021) Vol. 29, Iss. 3-4, pp. 157-170
Open Access | Times Cited: 60
Therapy development for spinal muscular atrophy: perspectives for muscular dystrophies and neurodegenerative disorders
Sibylle Jablonka, Luisa Hennlein, Michael Sendtner
Neurological Research and Practice (2022) Vol. 4, Iss. 1
Open Access | Times Cited: 52
Emerging Therapies and Novel Targets for TDP-43 Proteinopathy in ALS/FTD
Lindsey R. Hayes, Petr Kaláb
Neurotherapeutics (2022) Vol. 19, Iss. 4, pp. 1061-1084
Open Access | Times Cited: 43
Drug Discovery Perspectives of Antisense Oligonucleotides
Yeonjoon Kim
Biomolecules & Therapeutics (2023) Vol. 31, Iss. 3, pp. 241-252
Open Access | Times Cited: 27
2019 FDA TIDES (Peptides and Oligonucleotides) Harvest
Danah Al Shaer, Othman Al Musaimi, Fernando Alberício, et al.
Pharmaceuticals (2020) Vol. 13, Iss. 3, pp. 40-40
Open Access | Times Cited: 66
Gene Therapy for Neurodegenerative Diseases: Slowing Down the Ticking Clock
Raygene Martier, Pavlina Konstantinova
Frontiers in Neuroscience (2020) Vol. 14
Open Access | Times Cited: 63
In vivoandin vitrostudies of antisense oligonucleotides – a review
Anna Kilanowska, Sylwia Studzińska
RSC Advances (2020) Vol. 10, Iss. 57, pp. 34501-34516
Open Access | Times Cited: 58
Developing DMD therapeutics: a review of the effectiveness of small molecules, stop-codon readthrough, dystrophin gene replacement, and exon-skipping therapies
Omar Sheikh, Toshifumi Yokota
Expert Opinion on Investigational Drugs (2021) Vol. 30, Iss. 2, pp. 167-176
Closed Access | Times Cited: 56
Current Pharmacological Strategies for Duchenne Muscular Dystrophy
Shanshan Yao, Zihao Chen, Liang Yu, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 49
Hereditary Haemorrhagic Telangiectasia, an Inherited Vascular Disorder in Need of Improved Evidence-Based Pharmaceutical Interventions
Ryan O. Snodgrass, Tim Chico, Helen M. Arthur
Genes (2021) Vol. 12, Iss. 2, pp. 174-174
Open Access | Times Cited: 45
A cell-penetrating peptide enhances delivery and efficacy of phosphorodiamidate morpholino oligomers in mdx mice
Li Gan, Leslie C.L. Wu, Jenna Wood, et al.
Molecular Therapy — Nucleic Acids (2022) Vol. 30, pp. 17-27
Open Access | Times Cited: 30
Mechanisms of Action of the US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs
Angela Sang, S. Zhuo, Adara Bochanis, et al.
BioDrugs (2024) Vol. 38, Iss. 4, pp. 511-526
Closed Access | Times Cited: 7
Evaluating the potential of novel genetic approaches for the treatment of Duchenne muscular dystrophy
Vratko Himič, Kay E. Davies
European Journal of Human Genetics (2021) Vol. 29, Iss. 9, pp. 1369-1376
Open Access | Times Cited: 35
Mitochondrial hydrogen sulfide supplementation improves health in the C. elegans Duchenne muscular dystrophy model
Rebecca A. Ellwood, Jennifer Hewitt, Roberta Torregrossa, et al.
Proceedings of the National Academy of Sciences (2021) Vol. 118, Iss. 9
Open Access | Times Cited: 34
Antisense and Gene Therapy Options for Duchenne Muscular Dystrophy Arising from Mutations in the N-Terminal Hotspot
Harry Wilton-Clark, Toshifumi Yokota
Genes (2022) Vol. 13, Iss. 2, pp. 257-257
Open Access | Times Cited: 24
Therapeutic strategies for autism: targeting three levels of the central dogma of molecular biology
Derek Hong, Lilia M. Iakoucheva
Translational Psychiatry (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 16
Enhancing Antisense Oligonucleotide-Based Therapeutic Delivery with DG9, a Versatile Cell-Penetrating Peptide
Umme Sabrina Haque, Toshifumi Yokota
Cells (2023) Vol. 12, Iss. 19, pp. 2395-2395
Open Access | Times Cited: 14
RNA processing in skeletal muscle biology and disease
Emma R. Hinkle, Hannah J. Wiedner, Adam J. Black, et al.
Transcription (2018) Vol. 10, Iss. 1, pp. 1-20
Open Access | Times Cited: 41
Duchenne muscular dystrophy: an historical treatment review
Lineu César Werneck, Paulo José Lorenzoni, Renata Dal‐Prá Ducci, et al.
Arquivos de Neuro-Psiquiatria (2019) Vol. 77, Iss. 8, pp. 579-589
Open Access | Times Cited: 36
Page 1 - Next Page

Scroll to top